Cargando…
Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science
BACKGROUND: Contemporary therapies for metastatic castration-resistant prostate cancer (mCRPC) have shown survival improvements, which do not account for patient experience and health-related quality of life (HRQoL). METHODS: This literature review included a search of MEDLINE for randomized clinica...
Autores principales: | Nussbaum, N, George, D J, Abernethy, A P, Dolan, C M, Oestreicher, N, Flanders, S, Dorff, T B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868871/ https://www.ncbi.nlm.nih.gov/pubmed/26832363 http://dx.doi.org/10.1038/pcan.2015.42 |
Ejemplares similares
-
Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
por: Bui, Cat N., et al.
Publicado: (2016) -
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015) -
Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014) -
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014) -
Update on options for treatment of metastatic castration-resistant prostate cancer
por: Vishnu, Prakash, et al.
Publicado: (2010)